HFM
MRTX

Harvest Fund Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Harvest Fund Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-79
Closed -$17K – 884
2020
Q4 		$17K Sell
79
-226
-74% -$48.9K ﹤0.01% 512
2020
Q3 		$51K Buy
+305
New +$41.7K ﹤0.01% 378

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Harvest Fund Management's MRTX Position: Q1 2021 in Review

Harvest Fund Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 79 shares — an estimated $17K sold.

Harvest Fund Management first reported a position in MRTX in Q3 2020 and held it in 2 quarters. The position peaked at $51K in Q3 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

  • Harvest Fund Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Harvest Fund Management sold 79 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $17K.
  • Harvest Fund Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Harvest Fund Management's Mirati Therapeutics, Inc. Common Stock position peaked at $51K in Q3 2020.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Harvest Fund Management's 13F filing for Q1 2021, filed 13 May 2021.